Targeted synthetic drugs

AB0657 PREDICTING CARDIOVASCULAR EVENTS IN PATIENTS ON JAK INHIBITOR THERAPY: UTILIZING AGE AND DEPRIVATION DECILES: A COMPREHENSIVE STUDY ACROSS THREE HOSPITAL SITES IN THE UNITED KINGDOM
K. Sunmboye, T. Petrie

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1614-1615; DOI: 10.1136/annrheumdis-2024-eular.71
AB0665 FACTORS INFLUENCING ATTAINMENT OF LOW DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS DEVIATING FROM TREAT-TO-TARGET STRATEGY
Y. J. Song, S. K. Cho, J. Y. Han, S. B. Lee, H. R. Park, H. W. Kim, E. Nam, S. W. Lee, Y. K. Sung

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1619; DOI: 10.1136/annrheumdis-2024-eular.962
AB0667 THE EFFICACY OF FILGOTINIB IN RHEUMATOID ARTHRITIS MAY BE TIME-DEPENDENT. (IN VIEW OF THE HILL COEFFICIENT OF FILGOTINIB)
T. Yoshikawa, T. Abe, M. Tamura, T. Furukawa, T. Hashimoto, N. Azuma, K. Matsui

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1620; DOI: 10.1136/annrheumdis-2024-eular.990
AB0683 WHAT HAPPENS IN RHEUMATOID ARTHRITIS TREATMENT ADHERENCE, TWO YEARS AFTER THE INTRODUCTION OF TARGETED THERAPY? RESULTS FROM THE STRATEGE2 STUDY
C. Gaujoux-Viala, E. Dernis, E. Senbel, H. Herman-Demars, J. Becker, A. Courbeyrette, R. M. Flipo

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1628-1629; DOI: 10.1136/annrheumdis-2024-eular.2275
AB0689 SUSTAINED PATIENT MEANINGFUL OUTCOMES OF PAIN AND FATIGUE RELIEF AND IMPROVED PHYSICAL FUNCTIONING WITH FILGOTINIB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS
R. Alten, B. Fautrel, P. G. Conaghan, D. De Vries, M. Faes, M. Piovesan, K. Van Beneden, C. Watson, A. E. A. M. Weel-Koenders, E. Feist, K. De Vlam

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1633-1634; DOI: 10.1136/annrheumdis-2024-eular.2864
AB0692 IMPACT OF THE EVOLUTION IN RHEUMATOID ARTHRITIS THERAPEUTICS ON TREATMENT OUTCOMES: A COMPREHENSIVE ANALYSIS IN KURAMA COHORT
T. Fujii, K. Murata, H. Onizawa, A. Onishi, K. Murakami, M. Tanaka, A. Morinobu, S. Matsuda

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1635-1636; DOI: 10.1136/annrheumdis-2024-eular.3665
AB0704 A COMPARISON BETWEEN THE ADVERSE EVENTS OF THREE JAK INHIBITORS. A RETROSPECTIVE REAL-WORLD MULTICENTRE REGISTERY STUDY
A. S. Zayat, M. A. Omair, O. Alsaed, W. Hafiz, R. Namas, K. Ghassan Bohuliga, E. N. Etrug, A. Poil, M. Ahmed, N. Kalantan, A. M. Alragheb, S. Allam, A. Hussein, S. Attar, S. Hannawi, S. Alemadi

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1642-1643; DOI: 10.1136/annrheumdis-2024-eular.5008
AB0712 CLINICAL FEATURES OF RHEUMATOID ARTHRITIS PATIENTS ELIGIBLE FOR JAK-INHIBITOR THERAPY: AN ASSESSMENT BEFORE VERSUS AFTER EMA RECOMMENDATIONS TO MINIMIZE CARDIOVASCULAR, THROMBOEMBOLIC, AND NEOPLASTIC RISKS
E. Piovani, C. Barison, P. Bizioli, R. Martinelli, C. Bazzani, F. Franceschini

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1645-1646; DOI: 10.1136/annrheumdis-2024-eular.5445
AB0724 TOFACITINIB DRUG SURVIVAL MAY BE BETTER IN OBESE TNF INHIBITOR RESISTANT RA PATIENTS
E. Kayacan Erdoğan, B. Armagan, R. Kocak Ulucaköy, K. Orhan, S. C. Güven, B. Özdemir Ulusoy, H. E. Konak, Ö. Karakaş, P. Akyüz Dağli, E. Atalar, İ. Dogan, Y. Maraş, A. Omma, O. Küçükşahin, S. Erten, H. Babaoglu

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1652; DOI: 10.1136/annrheumdis-2024-eular.1726
AB0528 THERAPEUTIC EFFECACY OF JAK INHIBITORS WITH OR WITHOUT METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS
T. Okano, C. Yoshimura, K. Mamoto, Y. Yamada, T. Kojima, K. Inui, M. Tada, K. Orita, S. Anno, T. Iida, T. Koike

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1539-1540; DOI: 10.1136/annrheumdis-2024-eular.2734

Main menu

Targeted synthetic drugs

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Targeted synthetic drugs

Pages